Objective-Peroxisome proliferator-activated receptor-␣ (PPAR␣) activation has been shown in vitro to increase macrophage cholesterol efflux, the initial step in reverse cholesterol transport (RCT). However, it remains unclear whether PPAR␣ activation promotes macrophage RCT in vivo. Methods and Results-We demonstrated that a specific potent PPAR␣ agonist GW7647 inhibited atherosclerosis and promoted macrophage RCT in hypercholesterolemic mice expressing the human apolipoprotein A-I (apoA-I) gene. We compared the effect of GW7647 on RCT in human apoA-I transgenic (hA-ITg) mice with wild-type mice and showed that the PPAR␣ agonist promoted RCT in hA-ITg mice to a much greater extent than in wild-type mice, indicating that human apoA-I expression is important for PPAR␣-induced RCT. We further investigated the dependence of the macrophage PPAR␣-liver X receptor (LXR) pathway on the promotion of RCT by GW7647. Primary murine macrophages lacking PPAR␣ or LXR abolished the ability of GW7647 to promote RCT in hA-ITg mice. In concert, the PPAR␣ agonist promoted cholesterol efflux and ATP binding cassette transporter A1/G1 expression in primary macrophages, and this was also by the PPAR␣-LXR pathway. Conclusion-Our observations demonstrate that a potent PPAR␣ agonist promotes macrophage RCT in vivo in a manner that is enhanced by human apoA-I expression and dependent on both macrophage PPAR␣ and LXR expression. (Arterioscler Thromb Vasc Biol. 2011;31:1276-1282.) 
R everse cholesterol transport (RCT) is believed to be a primary atheroprotective property of high-density lipoprotein (HDL) and its major protein, apolipoprotein A-I (apoA-I), which promote efflux of excess cholesterol from macrophages in atherosclerotic lesions and then transport it back to the liver for excretion into bile and eventually the feces. 1 Cholesterol efflux is the initial step in RCT and plays a pivotal role in maintaining intracellular cholesterol levels and preventing the formation of macrophage-derived foam cells in atherosclerotic plaques. ATP binding cassette transporter A1 (ABCA1) has been shown to play an important role in apoA-I-mediated cholesterol efflux from peripheral cells and macrophages, whereas ABCG1 promotes cholesterol efflux from macrophages to HDL particles but not to lipidpoor apoA-I. 2, 3 ABCA1 and ABCG1 in macrophages act in synergy against atherosclerosis. 4 Moreover, we recently developed an assay that specifically traces RCT from the macrophages to the feces in vivo 5 and reported that both ABCA1 and ABCG1 in macrophage play critical roles in promoting macrophage RCT in vivo. 6 Peroxisome proliferator-activated receptors (PPARs) have been reported to regulate the expression of genes that control lipid metabolism by binding as heterodimers with retinoid X receptors to PPAR response element in the promoter or enhancer regions of these genes. 7 PPAR␣ is a member of this nuclear receptor superfamily that regulates gene expression in response to the binding of fatty acids and their metabolites, 8, 9 and it is expressed in the major cell types found in the atherosclerotic lesion, including macrophages, endothelial, and smooth muscle cells. 10 -12 PPAR␣ activation has been demonstrated in vitro to stimulate ABCA1 gene transcription, which in turn enhances cholesterol efflux. 13, 14 Moreover, these events have been suggested to involve upregulation of the liver X receptor (LXR), 13, 14 one of the main regulators of ABCA1 gene transcription, 15 although specific mechanisms for these cascades and their relevance to the in vivo setting are yet to be clarified.
In addition, studies in human apoA-I transgenic mice (hA-ITg) 16 and in human subjects 17 have established that PPAR␣ agonists promote human apoA-I gene transcription and its production. We reported that overexpression of human apoA-I promoted macrophage RCT in vivo. 18 In concert with these findings, Duez et al 19 demonstrated that human apoA-I expression is important for PPAR␣ agonist-mediated reduction in atherosclerosis using apoE-knockout (KO) mice with the human apoA-I transgene.
In the present study, we examined whether a potent PPAR␣ agonist promoted macrophage RCT in vivo in mice and whether its effect was conditioned by expression of human apoA-I and the expression of macrophage PPAR␣ and LXR.
Methods
An expanded Methods section appears in the Supplemental Data, available online at http://atvb.ahajournals.org.
hA-ITg and PPAR␣-KO mice were obtained from the Jackson Laboratory, and LXR␣/␤ double knockout (DKO) mice were obtained from Taconic. Low-density lipoprotein receptor (LDLR)/ apobec-1 DKO mice and hA-ITg mice were crossed to generate LDLR/Apobec-1 DKO/hA-ITg (LAA) mice. Lipids from fasted plasma and fast performance liquid chromatography samples were quantified using commercially available kits. Primary bone marrowderived macrophages (BMMs) were isolated from femurs and tibias of mice and cultured in Dulbecco's modified Eagle's medium supplemented with 30% L929 conditioned medium. Cholesterol efflux and in vivo RCT studies were performed using established methods. All studies were approved by the University of Pennsylvania Institutional Animal Care and Use Committee.
Results
The PPAR␣ Agonist GW7647 Inhibits the Development of Atherosclerosis in Hypercholesterolemic Mice Expressing Human ApoA-I LDLR/Apobec-1 DKO mice have elevated low-density lipoprotein (LDL) cholesterol and apoB-100 levels and develop extensive atherosclerosis on chow diet, 20 thus more closely resembling human atherosclerotic pathophysiology. To investigate potential effects of PPAR␣ activation on the development of atherosclerosis in this hypercholesterolemic murine model in the setting of human apoA-I expression driven by the PPAR␣-responsive human apoA-I promoter, we generated LAA mice and performed intervention studies using the potent and specific PPAR␣ agonist GW7647. GW7647 has a median effective concentration of 1 nmol/L for the murine PPAR␣, compared to 2.9 and 1.3 mol/L for murine PPAR␤ and PPAR␥, respectively. 21 LAA mice were fed chow diet with or without GW7647 for 24 weeks, and no adverse health effects were noted throughout the study. GW7647 treatment brought about a 2.3-fold increase in hepatic mRNA levels of acyl-coenzyme A oxidase (AOX), a canonical PPAR␣ target gene, compared with control treatment in the mice (Supplemental Figure I ).
GW7647 treatment significantly increased plasma HDL cholesterol and human apoA-I levels by 45% and 46%, respectively (Table) . Total cholesterol levels trended higher and triglyceride levels trended lower in the mice treated with GW7647 compared with control-treated mice, but neither were statistically significant. Analysis of lipoprotein profiles using fast performance liquid chromatography revealed a substantial increase in the HDL fraction but little change in the very-low-density lipoprotein and LDL fractions in the GW7647-treated group compared with the control group (Supplemental Figure IIA) .
The extent of atherosclerosis was determined in en face preparations of the aorta, as well as in sections of the aortic root. Representative examples of en face Oil Red O-stained aortas from LAA mice treated with GW7647 or control are shown in Figure 1A . When the extent of atherosclerotic lesion was quantified, GW7647 resulted in a significant decrease in atherosclerosis in the aorta by 35% ( Figure 1B ). We also quantified total lesion area in the aortic root. Representative sections are shown in Figure 1C . The mice treated with GW7647 demonstrated a significant 31% decrease in aortic root lesions compared with control mice ( Figure 1D ).
PPAR␣ Agonism Promotes Macrophage RCT in Hypercholesterolemic Mice Expressing Human ApoA-I
The enhancing effects of PPAR␣ on human apoA-I and HDL in LAA mice led us to hypothesize that its activation inhibited atherogenesis by promoting RCT. We therefore used methods developed in our laboratory 5 to investigate the impact of PPAR␣ agonism on macrophage RCT in LAA mice. Cholesterol-loaded and 3 H-cholesterol-labeled J774 macrophages were intraperitoneally injected into LAA mice that had been treated with GW7647 or control for 2 weeks. We then followed the 3 H-tracer levels in plasma at 6, 24, and 48 hours and in liver at 48 hours after injection. We also integrated the 3 H-tracer levels in feces collected through the 48-hour period. J774 macrophages were found to express PPAR␣ as detected by reverse transcription-polymerase chain reaction (data not shown). The appearance in plasma of macrophage-derived 3 H-tracer levels in LAA mice treated with GW7647 showed a nonsignificant trend toward an increase compared with control-treated mice ( Figure 1E ). Fractionation of lipoproteins at 48 hours revealed a substantially greater number of 3 H-tracer counts in the HDL fraction of GW7647-treated mice than in control mice (Supplemental Figure IIB) . Most importantly, GW7647 treatment significantly increased the levels of macrophage-derived 3 H-tracer excreted into feces by 98% ( Figure 1F ). These data indicate that PPAR␣ activation with GW7647 promotes macrophage RCT in LAA mice.
Human ApoA-I Expression Plays an Important Role in the Ability of Systemic PPAR␣ Activation to Promote Macrophage RCT
Next, we investigated whether transgenic human apoA-I expression contributed to PPAR␣-mediated macrophage 
The results for 10 mice from each group are presented as meanϮSD. Values were determined in plasma samples from fasting animals. *PϽ0.05.
RCT in vivo. We compared the effect of the PPAR␣ agonist on macrophage RCT in hA-ITg mice with that in wild-type (WT) mice to specifically evaluate the contribution of human apoA-I. GW7647 significantly increased AOX mRNA levels in the liver from both WT and hA-ITg mice (Supplemental Figure IIIA and IIIB), indicating that GW7647 efficiently activated PPAR␣ in both mice. As expected, in hA-ITg mice GW7647 induced plasma human apoA-I levels and liver human apoA-I gene expression (Supplemental Figure IIIC and IIID), resulting in a significant increase in plasma HDL cholesterol levels (Supplemental Figure IIIF) . GW7647 treatment also increased plasma HDL cholesterol levels in WT mice (Supplemental Figure IIIE ), but to a lesser extent than in hA-ITg mice. We performed a macrophage RCT assay in both WT and hA-ITg mice treated with GW7647 or control. The appearance in plasma of macrophage-derived 3 H-tracer levels in WT mice treated with GW7647 were modestly but significantly increased at 24 hours after injection (Figure 2A ). GW7647 also modestly but significantly induced 3 H-tracer levels in feces by 30% in WT mice ( Figure 2C ). In contrast, hA-ITg mice treated with GW7647 showed substantially greater 3 H-tracer levels in plasma at 24 and 48 hours after injection ( Figure 2B ). Moreover, the fecal 3 H-tracer excretion from GW7647-treated hA-ITg mice was increased by 108% ( Figure 2D ). Taken together, these observations suggest that PPAR␣-induced human apoA-I expression confers substantial enhancement of macrophage RCT in vivo induced by a PPAR␣ agonist.
Macrophage PPAR␣ Is Required for the Ability of Systemic PPAR␣ Activation to Promote Macrophage RCT
To further explore the mechanism of PPAR␣-mediated macrophage RCT, we tested whether systemic PPAR␣ activation required macrophage PPAR␣ to promote RCT using primary BMMs from PPAR␣-KO and WT mice. We confirmed that PPAR␣ was expressed in WT BMMs but not in PPAR␣-KO BMMs (data not shown). hA-ITg mice were treated with GW7647 or control for 2 weeks before injection of labeled BMMs from either PPAR␣-KO or WT mice and continued to be treated during the 48-hour experiment. The 3 H-tracer levels in plasma were significantly increased by GW7647 treatment in the mice injected with WT BMMs ( Figure 3A) . In contrast, GW7647 had no effect in the plasma 3 H-tracer levels in the mice injected with PPAR␣-KO BMMs ( Figure  3B ). GW7647 treatment also significantly increased fecal excretion of 3 H-tracer in WT BMM-injected mice by up to 60% but had no effect in the mice with PPAR␣-KO BMMs (Figure 3C and 3D) . These data confirm that macrophage PPAR␣ is required for the promotion of RCT by PPAR␣.
Next, to elucidate the molecular mechanisms underlying the enhanced macrophage RCT, we determined the impact of PPAR␣ activation on cholesterol efflux and expression of genes involved in the pathway in WT and PPAR␣-KO BMMs ex vivo. In WT BMMs, GW7647 treatment increased apoA-I-and HDL3-mediated cholesterol efflux by 42% and 18%, respectively, whereas in PPAR␣-KO BMMs, this treatment had no effect on cholesterol efflux ( Figure 4A and 4B ). Supporting the change in cholesterol efflux, GW7647 significantly increased expression of ABCA1/G1 mRNA ( Figure  4C and 4D) and protein (Supplemental Figure IV) levels in WT BMMs, whereas the treatment did not change their expression in PPAR␣-KO BMMs (Figure 4C and 4D) . Similar to the changes in ABCA1 and ABCG1, LXR␣ and AOX mRNA levels were also significantly increased by GW7647 treatment in WT BMMs, whereas these effects were canceled in PPAR␣-KO BMMs (Figure 4E and 4F ). GW7647 did not significantly change expression of macrophage scavenger receptor CD36, an established PPAR␥ target gene, or SR-BI (data not shown). Taken together, these findings suggest that PPAR␣ activation enhances cholesterol efflux by increasing ABCA1/G1 expression in primary murine macrophages, which in turn promotes overall RCT in vivo, in a macrophage PPAR␣-dependent manner.
Macrophage LXR Is Required for the Ability of Systemic PPAR␣ Activation to Promote Macrophage RCT
Finally, we investigated whether macrophage LXR is essential for the ability of PPAR␣ to promote RCT using BMMs from LXR␣/␤ DKO (LXR-DKO) mice. We performed macrophage RCT studies in hA-ITg mice with WT and LXR-DKO BMMs. GW7647 treatment significantly increased plasma 3 H-tracer levels at 24 and 48 hours in the mice injected with WT BMMs, but there was no effect in the mice injected with LXR-DKO BMMs (Figure 5A and 5B) . The fecal excretion of 3 H-tracer was also increased by GW7647 in WT BMM-injected mice by up to 188%, but it was not increased in LXR-DKO BMM-injected mice ( Figure 5C and 5D ). In ex vivo experiments, GW7647 significantly increased apoA-I-and HDL3mediated cholesterol efflux and ABCA1/G1 expression in WT BMMs, whereas this treatment had no effect in LXR-DKO BMMs (Figure 6A to 6D) . These observations indicate that the macrophage PPAR␣-LXR pathway plays a critical role in PPAR␣-induced macrophage RCT.
Discussion
In the present study, we demonstrated that PPAR␣ activation with the specific and potent agonist GW7647 inhibited the development of atherosclerosis and promoted macrophage RCT in LAA mice, a humanized hypercholesterolemic murine model expressing the human apoA-I gene. Next, we showed that GW7647 brought about a much higher rate of macrophage RCT and increased plasma human apoA-I levels in hA-ITg mice than in WT mice, suggesting that human apoA-I expression is important for the promotion of macrophage RCT by PPAR␣. We further determined the impact of the macrophage PPAR␣-LXR pathway on PPAR␣-mediated overall RCT. Interestingly, GW7647 significantly promoted macrophage RCT in hA-ITg mice injected with WT primary macrophages but not in the mice injected with macrophages lacking PPAR␣ or LXR. In ex vivo experiments, GW7647 also enhanced cholesterol efflux and ABCA1/G1 expression in primary macrophages by the PPAR␣-LXR pathway. Taken together, these observations suggest that PPAR␣ activation promotes macrophage RCT in a macrophage PPAR␣-and LXR-dependent fashion.
The stimulatory effect of PPAR␣ activation on human apoA-I expression has been well documented. Vu-Dac et al 22 reported that PPAR␣ agonist increased human apoA-I expression but not rodent apoA-I because of sequence divergences in the respective apoA-I promoters. We also demonstrated that PPAR␣ agonist upregulated apoA-I production in human subjects by kinetic studies. 17 Moreover, Duez et al 19 reported that a PPAR␣ agonist had minimal antiatherogenic effects in apoE-KO mice but exerted a more pronounced effect in apoE-KO mice carrying the human apoA-I transgene, suggesting that human apoA-I expression is crucial for the reduction in atherosclerosis by PPAR␣. In the present study, we therefore used LAA mice and hA-ITg mice to investigate the effect of PPAR␣ activation on atherosclerosis and RCT in mouse models with the human apoA-I gene, driven by the human apoA-I promoter which has PPAR␣responsive elements.
Consistent with the previous observations in humans, 16, [23] [24] [25] the PPAR␣ agonist strongly increased human apoA-I and HDL cholesterol levels in LAA mice. Therefore, we hypothesized that PPAR␣ inhibited atherogenesis by promoting macrophage RCT. As expected, in concert with its effect on atherosclerosis, GW7647 significantly promoted the fecal excretion of HDL-derived cholesterol and thus the overall pathway of macrophage RCT in LAA mice. Recently, Rotllan et al 26 also reported that a well-known PPAR␣ agonist fenofibrate promoted macrophage RCT, supporting that the effect of GW7647 on RCT is not an off-target effect.
ApoA-I is also present free in the circulation and interstitial space under varying degrees of lipidation. 27 It is therefore plausible that apoA-I associated with HDL may have direct effects on HDL antiatherogenic function. Abundant data from studies in animals have indicated that enhancement of human apoA-I expression inhibited atherosclerosis. 28, 29 We also reported that overexpression of human apoA-I promoted macrophage RCT in vivo, which is thought to contribute at least in part to its antiatherogenic properties. 18 Therefore, we investigated whether PPAR␣-induced human apoA-I expression results in the promotion of macrophage RCT. We compared the effect of GW7647 on macrophage RCT in hA-ITg mice with WT mice to specifically evaluate the contribution of human apoA-I and found that GW7647 treatment had a much higher rate of RCT in hA-ITg mice. These studies provide the first in vivo evidence of the substantial contribution of human apoA-I expression to the enhancement of macrophage RCT by PPAR␣, consistent with the previous study indicating the importance of human apoA-I in the inhibition of atherosclerosis by PPAR␣. 19 These observations also support the concept that the promotion of macrophage RCT may be a mechanism by which PPAR␣ activation functions to inhibit the development of atherosclerosis in the hypercholesterolemic mice.
It has been shown that PPAR␣ promotes cholesterol efflux from macrophages in vitro and that this may be related to upregulation of LXR expression. LXR, especially LXR␣, has been reported to be activated by oxysterols, and its primary function is to maintain cellular cholesterol homeostasis. It is therefore relevant that activation of LXR␣ leads to induction of the genes required for cholesterol efflux, such as those encoding ABCA1 and ABCG1 through the LXR response elements in their proximal promoters. 15 Moreover, Laffitte et al 30 reported that LXR agonist-induced ABCA1 and ABCG1 expression in macrophages was completely abolished by deletion of both LXR␣ and LXR␤. In fact, it was reported that PPAR␥ directly induces LXR␣ expression through a response element upstream of the LXR promoter region, leads to the induction of ABCA1, and then regulates a pathway of cholesterol efflux from macrophages. 31 PPAR␣ agonists also have been shown to induce ABCA1 expression and cholesterol efflux in macrophages in an LXR␣-dependent manner. [13] [14] In addition, it was recently reported that activation of LXR␣ enhanced not only ABCA1 but also PPAR␣ gene transcription, 32 indicating that the cellular regulation of cholesterol transport is via a complex pathway involving PPAR␣ and LXR.
A previous study using LDLR-KO mice reconstituted with bone marrow from PPAR␣-KO mice demonstrated that macrophage PPAR␣ conferred antiatherogenic effects via modulation of macrophage cholesterol metabolism. 33 Moreover, our present data suggested that an important factor in the promotion of overall RCT by the PPAR␣ agonist was likely to be the enhancement of cholesterol efflux from the injected macrophages, which was reflected in the increased plasma tracer levels. We therefore examined whether the macrophage PPAR␣-LXR pathway plays a crucial role in the promotion of RCT by PPAR␣ using primary bone marrow macrophages lacking PPAR␣ or LXR. Interestingly, primary macrophages lacking PPAR␣ or LXR completely abolished PPAR␣-induced overall RCT in vivo, indicating the critical role of macrophage PPAR␣ and LXR in RCT. In ex vivo experiments, we also demonstrated that PPAR␣ activation enhanced cholesterol efflux and ABCA1/G1 gene expression through the PPAR␣-LXR pathway. Because we previously reported that macrophage ABCA1 and ABCG1 promoted RCT in vivo and were additive in their effects, 6 our in vivo and ex vivo findings are consistent with the concept that PPAR␣ activation enhances cholesterol efflux in association with increased expression of ABCA1/G1 in macrophages, resulting in promotion of overall RCT, by the PPAR␣-LXR pathway.
The above observations also suggest that modest promotion of RCT by PPAR␣ in WT mice might be mainly due to enhanced cholesterol efflux from macrophages. Moreover, because macrophage PPAR␣ and LXR were required for the promotion of RCT even in the condition with increased human apoA-I expression, the ability of human apoA-I to promote RCT may require the interaction with the macrophage PPAR␣-LXR pathway. Thus, further investigation is needed to elucidate the exact mechanisms.
On the other hand, several recent studies have provided conflicting results on the roles of PPAR␣ in ABCA1 and ABCG1 expression in macrophages. Li et al 34 showed that PPAR␣ agonist inhibited foam-cell formation in cholesterolloaded murine peritoneal macrophages in an LXR-dependent manner but did not affect ABCA1 expression. Babaev et al 33 also reported that PPAR␣ agonist treatment had a trend for increases in ABCA1 and ABCG1 expression in WT peritoneal macrophages, but these were not significant. The discrepancies between these studies and our results might be partly ascribed to differences between peritoneal macrophages, which are stimulated by thioglycollate, and BMMs. Moreover, PPAR␣ agonists have been reported to inhibit proinflammatory pathways by antagonizing nuclear factor-B or activator protein-1. 35, 36 Clearly, macrophage cholesterol efflux and RCT constitute one factor involved in the overall impact of PPAR␣ on atherosclerosis, and other factors, including inhibition of inflammation, can also have effects on atherosclerosis besides those of RCT.
In summary, we have demonstrated that PPAR␣ activation with a specific agonist inhibits the development of atherosclerosis and promotes macrophage RCT in humanized hypercholesterolemic mice expressing the human apoA-I gene.
We also show that human apoA-I expression is important for PPAR␣-mediated macrophage RCT. More interestingly, macrophage PPAR␣ and LXR expression are critical for the ability of PPAR␣ to promote cholesterol efflux and overall RCT. These results indicate that PPAR␣ exerts an antiatherogenic property by promoting RCT through the macrophage PPAR␣-LXR pathway, and they are consistent with the concept that specific and potent PPAR␣ activation might be expected to enhance macrophage RCT in humans.
